ROSSARI.NS
Rossari Biotech Limited [ROSSARI.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ROSSARI.NS Stock Summary
Top 10 Correlated Stocks
ROSSARI.NS
In the News
ROSSARI.NS Financial details
Company Rating
Buy
Market Cap
40.04B
Income
1.26B
Revenue
17.64B
Book val./share
-
Cash/share
-
Dividend
0.5
Dividend %
0.06%
Employees
500
Optionable
No
Shortable
Yes
Earnings
27 Apr 2024
P/E
37.9
Forward P/E
-
PEG
13.66
P/S
2.62
P/B
4.53
P/C
-
P/FCF
4698.92
Quick Ratio
1.06
Current Ratio
1.8
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
22.75
EPS next Y
-
EPS next Q
-
EPS this Y
9.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
15.57%
Revenue last 5Y
26.4%
Revenue Q/Q
-4.07%
EPS Q/Q
4.36%
-
-
-
-
SMA20
1.26%
SMA50
-7.56%
SMA100
0.28%
Inst Own
-
Inst Trans
-
ROA
8%
ROE
25%
ROC
0.15%
Gross Margin
30%
Oper. Margin
10%
Profit Margin
7%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
656.95-903.85
52W High
-19.51%
52W Low
+10.8%
RSI
56
Rel Volume
0.75
Avg Volume
78.52K
Volume
59.28K
Perf Week
2.09%
Perf Month
-1.82%
Perf Quarter
-4.78%
Perf Half Y
-10.07%
-
-
-
-
Beta
0.151
-
-
Volatility
11.04%, 19.42%
Prev Close
-1.07%
Price
726.85
Change
-1.83%
ROSSARI.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 106.02 | 123.03 | 137.19 | 268.96 | 300.44 | |
| Net income per share | 9.44 | 13.42 | 15.56 | 17.81 | 19.46 | |
| Operating cash flow per share | 14.71 | 11.28 | 9.26 | 5.35 | 27.65 | |
| Free cash flow per share | 5.62 | -4.35 | -2 | -1.62 | 21.69 | |
| Cash per share | 1.32 | 29.81 | 17.14 | 11.75 | 27.54 | |
| Book value per share | 25.58 | 58.96 | 79.27 | 146.8 | 166.05 | |
| Tangible book value per share | 24.35 | 57.98 | 76.68 | 99.3 | 116.51 | |
| Share holders equity per share | 25.58 | 58.96 | 79.27 | 146.8 | 166.05 | |
| Interest debt per share | 1.53 | 14.5 | -0.47 | 3.84 | 17.46 | |
| Market cap | 35.9B | 36.06B | 53.4B | 50B | 32.85B | |
| Enterprise value | 35.88B | 36.44B | 53.25B | 49.71B | 32.89B | |
| P/E ratio | 78.58 | 55.26 | 66.56 | 51.18 | 30.63 | |
| Price to sales ratio | 7 | 6.03 | 7.55 | 3.39 | 1.98 | |
| POCF ratio | 50.43 | 65.77 | 111.79 | 170.31 | 21.56 | |
| PFCF ratio | 132.04 | -170.54 | -517.58 | -563.88 | 27.49 | |
| P/B Ratio | 28.99 | 12.58 | 13.06 | 6.21 | 3.59 | |
| PTB ratio | 28.99 | 12.58 | 13.06 | 6.21 | 3.59 | |
| EV to sales | 6.99 | 6.09 | 7.53 | 3.37 | 1.99 | |
| Enterprise value over EBITDA | 45.53 | 33.6 | 40.98 | 25.38 | 14.34 | |
| EV to operating cash flow | 50.41 | 66.45 | 111.47 | 169.32 | 21.59 | |
| EV to free cash flow | 131.99 | -172.33 | -516.1 | -560.61 | 27.52 | |
| Earnings yield | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 | |
| Free cash flow yield | 0.01 | -0.01 | 0 | 0 | 0.04 | |
| Debt to equity | 0.04 | 0.23 | -0.01 | 0.01 | 0.08 | |
| Debt to assets | 0.02 | 0.14 | -0.01 | 0.01 | 0.05 | |
| Net debt to EBITDA | -0.02 | 0.35 | -0.12 | -0.15 | 0.02 | |
| Current ratio | 1.31 | 2.19 | 2.36 | 2.07 | 2.08 | |
| Interest coverage | 22.81 | 24.73 | 33.5 | 10.21 | 6.8 | |
| Income quality | 1.12 | 0.62 | 0.45 | 0.22 | 1.06 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.23 | 0.04 | 0.03 | 0.03 | 0.03 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0.01 | 0.02 | 0.21 | 0.2 | |
| Capex to operating cash flow | -0.62 | -1.39 | -1.22 | -1.3 | -0.22 | |
| Capex to revenue | -0.09 | -0.13 | -0.08 | -0.03 | -0.02 | |
| Capex to depreciation | -3.59 | -4.51 | -2.54 | -0.8 | -0.52 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 73.71 | 133.44 | 166.58 | 242.55 | 269.64 | |
| ROIC | 0.37 | 0.18 | 0.19 | 0.11 | 0.11 | |
| Return on tangible assets | 0.19 | 0.14 | 0.15 | 0.1 | 0.1 | |
| Graham Net | -3.8 | 16.75 | 18.14 | -11.34 | 10.72 | |
| Working capital | 379.61M | 1.78B | 2.05B | 3.15B | 3.74B | |
| Tangible asset value | 1.18B | 2.82B | 3.95B | 5.45B | 6.42B | |
| Net current asset value | 337.25M | 1.41B | 2.02B | 1.58B | 2.69B | |
| Invested capital | 0.04 | 0.23 | -0.01 | 0.01 | 0.08 | |
| Average receivables | 828.56M | 1.11B | 1.35B | 2.27B | 3.3B | |
| Average payables | 749.7M | 1.01B | 1.14B | 1.59B | 1.86B | |
| Average inventory | 447.57M | 565.35M | 767.62M | 1.43B | 1.89B | |
| Days sales outstanding | 70 | 75.03 | 75.74 | 75.86 | 78.02 | |
| Days payables outstanding | 111.29 | 92.91 | 99.98 | 61.17 | 57.71 | |
| Days of inventory on hand | 57.65 | 55.72 | 72.71 | 62.41 | 58.73 | |
| Receivables turnover | 5.21 | 4.86 | 4.82 | 4.81 | 4.68 | |
| Payables turnover | 3.28 | 3.93 | 3.65 | 5.97 | 6.33 | |
| Inventory turnover | 6.33 | 6.55 | 5.02 | 5.85 | 6.21 | |
| ROE | 0.37 | 0.23 | 0.2 | 0.12 | 0.12 | |
| Capex per share | -9.09 | -15.63 | -11.26 | -6.97 | -5.97 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 70.58 | 73.69 | 74.45 | 87.6 | 83.96 | |
| Net income per share | 4.66 | 5.25 | 5.3 | 5.97 | 6.23 | |
| Operating cash flow per share | 5.79 | 0.17 | 5.12 | 5.48 | 5.46 | |
| Free cash flow per share | 5.79 | 0.17 | 5.12 | 5.48 | 5.46 | |
| Cash per share | 13.39 | 27.52 | 27.36 | 15.03 | 0 | |
| Book value per share | 155.76 | 165.92 | 165.92 | 177.26 | 0 | |
| Tangible book value per share | 0 | 116.43 | 0 | 127.73 | 0 | |
| Share holders equity per share | 155.76 | 165.92 | 165.92 | 177.26 | 0 | |
| Interest debt per share | 0.85 | 14.19 | 1.15 | 24.76 | 0.78 | |
| Market cap | 40.1B | 32.88B | 47.98B | 44.96B | 44.15B | |
| Enterprise value | 40.84B | 32.92B | 49.49B | 45.77B | 44.15B | |
| P/E ratio | 39.04 | 28.36 | 41.05 | 34.11 | 32.09 | |
| Price to sales ratio | 10.3 | 8.09 | 11.68 | 9.3 | 9.52 | |
| POCF ratio | 125.65 | 3.49K | 169.96 | 148.74 | 146.3 | |
| PFCF ratio | 125.65 | 3.49K | 169.96 | 148.74 | 146.3 | |
| P/B Ratio | 4.67 | 3.59 | 5.24 | 4.6 | 0 | |
| PTB ratio | 4.67 | 3.59 | 5.24 | 4.6 | 0 | |
| EV to sales | 10.49 | 8.1 | 12.05 | 9.47 | 9.52 | |
| Enterprise value over EBITDA | 73.86 | 57.16 | 85.7 | 70.47 | 65.7 | |
| EV to operating cash flow | 127.97 | 3.49K | 175.31 | 151.42 | 146.3 | |
| EV to free cash flow | 127.97 | 3.49K | 175.31 | 151.42 | 146.3 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
| Debt to equity | 0 | 0.08 | 0 | 0.13 | 0 | |
| Debt to assets | 0 | 0.05 | 0 | 0.09 | 0 | |
| Net debt to EBITDA | 1.34 | 0.07 | 2.61 | 1.25 | 0 | |
| Current ratio | 0 | 2.08 | 0 | 1.8 | 0 | |
| Interest coverage | 8.43 | 6.93 | 6.91 | 9.91 | 12.05 | |
| Income quality | 1.24 | 0.03 | 0.97 | 0.92 | 0.88 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0.02 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.2 | 0 | 0.18 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 127.75 | 140.05 | 140.63 | 154.31 | 0 | |
| ROIC | 0.03 | 0.02 | 0.04 | 0.03 | 0 | |
| Return on tangible assets | 0 | 0.03 | 0 | 0.03 | 0 | |
| Graham Net | 13.39 | 10.71 | 27.36 | -3.67 | 0 | |
| Working capital | 738.41M | 3.74B | 1.51B | 3.74B | 0 | |
| Tangible asset value | 0 | 6.42B | 0 | 7.05B | 0 | |
| Net current asset value | 738.41M | 2.69B | 1.51B | 2.87B | 0 | |
| Invested capital | 0 | 0.08 | 0 | 0.13 | 0 | |
| Average receivables | 1.76B | 1.77B | 1.77B | 2.08B | 2.08B | |
| Average payables | 942.24M | 925.93M | 925.93M | 1.1B | 1.1B | |
| Average inventory | 994.61M | 942.39M | 942.39M | 1.41B | 1.41B | |
| Days sales outstanding | 0 | 78.37 | 0 | 77.28 | 0 | |
| Days payables outstanding | 0 | 58.22 | 0 | 57.61 | 0 | |
| Days of inventory on hand | 0 | 59.26 | 0 | 74.27 | 0 | |
| Receivables turnover | 0 | 1.15 | 0 | 1.16 | 0 | |
| Payables turnover | 0 | 1.55 | 0 | 1.56 | 0 | |
| Inventory turnover | 0 | 1.52 | 0 | 1.21 | 0 | |
| ROE | 0.03 | 0.03 | 0.03 | 0.03 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ROSSARI.NS Frequently Asked Questions
What is Rossari Biotech Limited stock symbol ?
Rossari Biotech Limited is a IN stock and trading under the symbol ROSSARI.NS
What is Rossari Biotech Limited stock quote today ?
Rossari Biotech Limited stock price is $726.85 today.
Is Rossari Biotech Limited stock public?
Yes, Rossari Biotech Limited is a publicly traded company.
Something similar
Company Profile
- Volume Average 78.52K
- Market Capitalization 40.04B
- Employee 500
- CEO Mr. Puneet Arora
- Headquarters Mumbai,IN
- IPO Date 2020-07-23
-
Website
https://www.rossari.com 
Rossari Biotech Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names. In addition, it provides poultry nutrition products comprising vitamin-mineral formulations, toxin binders, individual and cocktail enzymes, liquid nutraceuticals, and supplements or herbal preparations. The company was formerly known as Rossari Labtech and changed its name to Rossari Biotech Limited in December 2003. Rossari Biotech Limited was founded in 2003 and is based in Mumbai, India.
